NASDAQ Biotechnology Index up and climbing Developing new treatment for acute myeloid leukemia (AML) Lead candidate, Annamycin, now at phase II Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date … Continue reading “Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment”
Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO”
Oncology pipeline features significant safety/efficacy advantages Lead candidate poised for FDA acceleration due to significant unmet need in AML Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch””
Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial”
Shares of Moleculin Biotech (NASDAQ: MBRX) are up more than 30% after the company said that WP1234, a metabolic inhibitor, is a positive drug candidate to be studied for the potential to treat pancreatic cancer. Pancreatic cancer is still considered mostly untreatable, so any improvement in treating this disease could symbolize a significant clinical benefit. … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise”
Moleculin Biotech (NASDAQ: MBRX) is a preclinical-stage pharmaceutical company that focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at LD Micro 2017 Invitational”
Moleculin Biotech (NASDAQ: MBRX) shares are 31% higher mid-morning after the company said it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Annamycin for the treatment of acute myeloid leukemia (AML). This designation will provide the company several benefits, such as tax credits for qualified clinical trials costs, exemptions … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Shares Spike on Orphan Drug Designation for Annamycin”
Moleculin Biotech (NASDAQ: MBRX) is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukaemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at 29th Annual Roth Conference”
Moleculin Biotech (NASDAQ: MBRX) shares tumbled 20% at market open after the company priced an underwritten public offering of its securities. The offering is comprised of 3,710,000 units at a public offering price of $1.35 per unit. Moleculin anticipates gross proceeds of approximately $5 million. The offering is expected to close on or about February … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Prices $5M Public Offering; Shares Lower”
Moleculin Biotech (NASDAQ: MBRX) is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). Moleculin Biotech also has two … Continue reading “Moleculin Biotech (MBRX) Starts Presentation at LD Micro Main Event”
